KeyBank National Association’s Tarsus Pharmaceuticals TARS Stock Holding History

KeyBank National Association’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$411K	Sell	6,528 -2,310	-26%	-$148K	﹤0.01%	1008
2026 Q1	$620K	Sell	8,838 -1,867	-17%	-$130K	﹤0.01%	736
2025 Q4	$877K	Sell	10,705 -1,678	-14%	-$125K	﹤0.01%	620
2025 Q3	$736K	Sell	12,383 -24	-0.2%	-$1.18K	﹤0.01%	648
2025 Q2	$503K	Buy	12,407 +24	+0.2%	+$1.08K	﹤0.01%	773
2025 Q1	$636K	Hold	12,383	–	–	﹤0.01%	673
2024 Q4	$686K	Buy	12,383 +2,404	+24%	+$109K	﹤0.01%	667
2024 Q3	$328K	Buy	9,979 +2,310	+30%	+$64.9K	﹤0.01%	943
2024 Q2	$208K	Buy	7,669 +1,940	+34%	+$65.2K	﹤0.01%	1043
2024 Q1	$208K	Buy	+5,729	New	+$168K	﹤0.01%	1040

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

KeyBank National Association's TARS Position: Q2 2026 in Review

KeyBank National Association reduced its Tarsus Pharmaceuticals (TARS) stake by 26% in Q2 2026, selling an estimated $148K and leaving 6,528 shares worth $411K. The position accounts for ﹤0.01% of the portfolio, ranked #1008.

KeyBank National Association first reported a position in TARS in Q1 2024 and has held it in 10 quarters since. The position peaked at $877K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

KeyBank National Association held 6,528 shares of Tarsus Pharmaceuticals worth $411K as of Q2 2026.
KeyBank National Association sold 2,310 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $148K.
Tarsus Pharmaceuticals made up ﹤0.01% of KeyBank National Association's portfolio in Q2 2026, its #1008 holding.
KeyBank National Association first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
KeyBank National Association's Tarsus Pharmaceuticals position peaked at $877K in Q4 2025.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.